This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Viral Infections  • Diagnosis  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Thomas McGinn, MD, MPH; Nicola O’Connor-Moore, MPH, RN; David Alfandre, MD, MSPH; Donald Gardenier, MS, MPA, APRN; Juan Wisnivesky, MD, MPH

Arch Intern Med. 2008;168(18):2009-2013.

Background  Although hepatitis C virus (HCV) has an estimated national prevalence of 1.8%, testing rates are lower than those recommended by guidelines, particularly in primary care. A critical step is the ability to identify patients at increased risk who should be screened. We sought to prospectively derive and validate a clinical predication tool to assist primary care providers in identifying patients who should be tested for HCV antibodies.

Methods  A total of 1000 randomly selected patients attending an inner-city primary care clinic filled out a 27-item questionnaire assessing 5 HCV risk factor domains: work, medical, exposure, personal care, and social history. Afterward, the patients underwent HCV antibody testing. Multivariable logistic regression analysis was performed to identify risk factors associated with HCV antibodies.

Results  There was an 8.3% (95% confidence interval, 6.7%-10.2%) prevalence of HCV antibodies. The patients who were HCV antibody positive were more likely to be male, older, and insured by Medicaid (P  .02). Those who had risk factors within the medical, exposure, and social history domains were more likely to be HCV antibody positive. The area under the receiver operating characteristic curve for the screening tool based on these 3 domains was 0.77. With an increasing number of positive domains, there was a higher likelihood of HCV antibody positivity. Only 2% of patients with 0 risk factors had HCV antibodies.

Conclusions  A prediction tool can be used to accurately identify patients at high risk of HCV who may benefit from serologic screening. Future studies should assess whether wider use of this tool may lead to improved outcomes.

Author Affiliations: Divisions of General Internal Medicine (Drs McGinn, Alfandre, and Wisnivesky and Mr Gardenier) and Pulmonary and Critical Care Medicine (Dr Wisnivesky), Mount Sinai School of Medicine, New York, New York; and Westchester Medical Center, Valhalla, New York (Ms O’Connor-Moore).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Overestimation of HCV Prevalence by Assessing Positive Anti-HCV Results Only
Ana M. Contreras and Rodolfo J. Ochoa-Jiménez
Arch Intern Med. 2009;169(9):903-904.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Assessment and proposal of a new combination of screening criteria for hepatitis C in France
King et al.
Eur J Public Health 2009;19:527-533.
ABSTRACT | FULL TEXT  

Overestimation of HCV Prevalence by Assessing Positive Anti-HCV Results Only
Contreras and Ochoa-Jimenez
Arch Intern Med 2009;169:903-904.
FULL TEXT